Episodes 1-12 of 12
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Consensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
CME/CEConsensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
